GLP-1 Calorie Targets 2026: Mounjaro, Ozempic AU Guide

Phase 3 trials of tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy) paired the drug with a 2,090 kJ (500 kcal) daily deficit, not the drug alone. For an average Australian adult on full-dose therapy, the daily target lands around 6,600 kJ (1,575 kcal) once tolerance settles, with protein at 1.2 to 1.6 g per kg of body weight to protect lean mass. Real-world data show most users never reach the maximum dose and average about half the trial weight loss, so targets that ignore your actual dose and intake are likely to miss in both directions.

GLP-1 receptor agonists do most of their work by quieting appetite signalling, not by rewriting metabolism. The 20.2 percent average weight loss with tirzepatide in SURMOUNT-5 and the 13.7 percent with semaglutide in the same trial were achieved against a prescribed lifestyle program: 500 kcal below estimated maintenance, at least 150 minutes of moderate activity per week, and protein-forward meals. Skip the program and the drug still works, but the numbers regress toward the real-world median, where 12-month weight loss is closer to 7.7 percent on semaglutide and 12.4 percent on tirzepatide. This guide gives you Australia-specific calorie and protein targets matched to the dose you are actually on, drawn from the same trial protocols regulators reviewed when TGA approved Mounjaro for weight management in September 2024.

The numbers below are reference figures, not a prescription. GLP-1 dosing, escalation, and side-effect management are decisions for the doctor who prescribed you the medication and the dietitian or APD who supports your plan. Use this post to walk into those conversations with the right questions.

What daily calorie target did GLP-1 trials actually use?

SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide) both prescribed a 2,090 kJ (500 kcal) per day deficit below each participant's estimated total daily energy expenditure, paired with 150 minutes per week of moderate aerobic activity. For an Australian adult against the 8,700 kJ menu-label reference, that maps to roughly 6,600 kJ per day; for a higher-need adult at 10,500 kJ maintenance, around 8,400 kJ per day.

The trial protocols are publicly available through the NEJM and SURMOUNT-1 publications. Both used the same lifestyle structure: a dietitian or qualified health professional estimated each participant's maintenance energy needs, subtracted 500 kcal, and provided counselling on healthful balanced meals. SURMOUNT-1 specified a protein-moderate split (25-30 percent protein, 40 percent carbohydrate, 30-35 percent fat) and 150 minutes of weekly activity. These are the inputs that produced the 16.0, 21.4, and 22.5 percent weight loss results at the 5 mg, 10 mg, and 15 mg tirzepatide doses over 72 weeks.

The Australian reference for "average adult maintenance" is the 8,700 kJ figure prescribed in the Food Standards Code and shown on every chain-restaurant menu board. That number is a population average drawn from national surveys, not a personal target — adult women typically sit at 8,000 to 8,700 kJ per day for maintenance and adult men at 8,700 to 10,500 kJ, with substantial variation by body size and activity. The SURMOUNT-1 deficit math, applied to common AU maintenance estimates, looks like this:

A practical caveat: GLP-1s often suppress appetite enough that the prescribed 500 kcal deficit feels like 1,000 kcal. Trial participants reported eating less than the protocol required, particularly during dose escalation weeks. Tracking actual intake — rather than assuming the deficit equals the target — is the single most useful piece of information for the prescriber managing your therapy. Research suggests under-eating below 5,200 kJ (1,250 kcal) per day for sustained periods correlates with greater lean-mass loss and slower long-term progress.

How does the dose escalation schedule change calorie targets?

Both Mounjaro and Ozempic start at a low tolerance dose with limited appetite effect and step up every 4 weeks. Calorie intake usually drops most steeply through the first two escalation steps as nausea and early satiety peak, then partially rebounds. A target that stays fixed at maintenance minus 500 kcal across all weeks may be too aggressive during the first month and too lenient by maintenance month 6.

The TGA-approved escalation schedule for tirzepatide (Mounjaro) starts at 2.5 mg once weekly for 4 weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg, with a 4-week interval at each step. For semaglutide (Ozempic and Wegovy), Australian product information starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, with 4-week intervals. Real-world data from a 2025 academic obesity clinic showed only 22.9 percent of semaglutide patients ever reached the maximum 2.4 mg dose, and only 28.3 percent of tirzepatide patients reached 15 mg. Most users stay at intermediate doses for tolerability or supply reasons.

Here is how the trial-style targets map against the escalation steps for an Australian adult with an estimated 8,700 kJ maintenance:

The 2025 Diabetes, Obesity and Metabolism analysis of dose persistence found medication discontinuation rates of 14, 24, 35, and 50 percent at 3, 6, 9, and 12 months respectively. The single most common cited reason was tolerability — most often nausea or vomiting at the higher steps. Adjusting calorie targets upward during escalation weeks (or pausing the climb to the next dose) is the lever clinicians use to keep patients on therapy long enough to see the trial-style results.

How much protein do you need on a GLP-1 to protect lean mass?

Current expert guidance, including from Mass General's obesity program and a 2024 consensus paper on GLP-1 muscle preservation, points to 1.2 to 1.6 g of protein per kg of current body weight per day during active weight loss, distributed across 3 to 4 meals at roughly 30 to 40 g per meal. Research suggests without intentional protein intake and resistance training, up to 40 percent of weight lost on GLP-1 therapy can come from lean tissue.

The lean-mass loss problem is the most underappreciated risk in GLP-1 therapy. DXA imaging across multiple trials shows that 25 to 40 percent of total weight lost is fat-free mass — a mix of muscle, organ tissue, and water. In sedentary participants without targeted protein intake, the fat-free fraction climbs higher. The Mass General Advances in Motion review concluded that "combining a high protein diet and consistent exercise with GLP-1 treatment has the greatest benefit in preserving bone and muscle mass, compared to diet alone or high protein diet alone."

Protein targets in absolute grams for common Australian adult body weights:

A daily protein checklist that works in practice:

The pre and post-workout nutrition guide extends this with specific intra-day timing strategies that translate well to GLP-1 schedules.

How do you track calories accurately when appetite is suppressed?

Suppressed appetite distorts the usual self-report bias in calorie tracking. Most untreated users under-report intake by around 20 percent; GLP-1 users frequently over-estimate intake instead because eating feels effortful even when portions are small. The reliable method is to weigh primary protein and carbohydrate sources, photo-log mixed plates, and audit the weekly average rather than any single day.

A 2024 Australian survey of GLP-1 users found tracking discontinuation was common: roughly half the respondents reduced or stopped logging within 90 days, citing "the app feels exhausting when I'm not hungry anyway." This is the opposite failure mode of pre-medication tracking, where the friction of estimating large meals leads to under-counting. On a GLP-1, the friction of estimating small portions leads to skipping logs entirely, which leaves the prescriber without the intake data needed to manage dose decisions.

The most accurate tracking workflow on GLP-1 therapy:

What happens to calorie needs when you stop the medication?

Weight regain after GLP-1 discontinuation is the rule, not the exception. STEP 4 reported that participants who switched from semaglutide to placebo regained roughly two-thirds of their lost weight within 12 months. The mechanism is reversed appetite suppression colliding with a lower post-loss maintenance number, so daily calorie needs at the new lower weight are 1,200 to 2,500 kJ below pre-treatment maintenance.

The biology is straightforward and not unique to GLP-1s. Any sustained weight loss reduces total daily energy expenditure proportional to the new lower body mass plus a small adaptive component on top. The 2016 Hall analysis of the Biggest Loser cohort showed adaptive thermogenesis can add 200 to 500 kcal of additional daily reduction beyond what body mass loss alone predicts, and SURMOUNT-3 found similar adaptation in tirzepatide responders. When the appetite-suppressing medication stops, hunger returns to its native level — but the calorie ceiling does not.

For a 90 kg adult who reached 70 kg on tirzepatide, the maintenance estimate using Mifflin-St Jeor drops roughly:

A 2026 expectation-setting note worth saying out loud: GLP-1 therapy is increasingly understood as long-term, not short-term, medication for most chronic-obesity patients. The American Diabetes Association and Endocrine Society both treat it as analogous to long-term antihypertensives — the underlying biology does not resolve with a 12-month course. PBS subsidy for Wegovy is currently expected to commence mid-2026 in Australia for adults with established cardiovascular disease and obesity, which may reduce the cost-driven discontinuation pattern that currently dominates real-world data.

Frequently Asked Questions

What is the typical daily calorie target on Mounjaro or Ozempic in Australia?

The SURMOUNT-1 and STEP 1 trial protocols both prescribed a 2,090 kJ (500 kcal) deficit below estimated maintenance, paired with 150 minutes of weekly activity and 25-30 percent protein. For an average Australian adult against the 8,700 kJ menu-label reference, that maps to roughly 6,600 kJ (1,575 kcal) per day. Higher-need adults at 10,500 kJ maintenance would target around 8,400 kJ per day. Individual targets vary with body size, activity, and dose — work with the prescribing clinician or an Accredited Practising Dietitian to set your specific number.

How much protein should I eat on a GLP-1?

Current expert guidance for adults during active weight loss on GLP-1 therapy is 1.2 to 1.6 g of protein per kg of current body weight per day, ideally split across 3 to 4 meals. A 90 kg adult therefore aims at 108 to 144 g of protein daily. Research suggests this range combined with 2 to 3 weekly resistance training sessions meaningfully reduces the proportion of lost weight that comes from lean tissue.

Does Mounjaro work better than Ozempic for weight loss?

In the head-to-head SURMOUNT-5 trial published in 2025, tirzepatide (Mounjaro) produced a mean 20.2 percent body weight loss over 72 weeks versus 13.7 percent for semaglutide (Ozempic at lower doses, Wegovy at higher) — a 6.5 percentage point difference favouring tirzepatide. Real-world 12-month data show smaller absolute losses for both: 12.4 percent on tirzepatide and 7.7 percent on semaglutide. Individual response varies substantially, and tolerability often determines outcomes more than mean efficacy.

Is Mounjaro PBS subsidised in Australia?

No. As of June 2026, Mounjaro is TGA approved for weight management (since September 2024) but is not PBS subsidised for weight loss. Private monthly cost ranges roughly AUD $280 to $750 depending on dose and pharmacy. Wegovy received a positive PBAC recommendation in November 2025 and PBS listing is expected mid-2026 for adults with established cardiovascular disease and obesity. Ozempic is PBS subsidised only for type 2 diabetes, not weight loss.

What if I cannot eat enough to hit my calorie target on a GLP-1?

Sustained intake well below estimated maintenance (commonly under 5,000 kJ per day for an average adult) correlates with greater lean-mass loss, fatigue, nausea worsening, and earlier discontinuation in published cohorts. Prioritising protein-dense, energy-efficient foods like Greek yoghurt, whey isolate, tinned fish, and eggs helps. If intake stays low for more than a week or two, the prescriber may pause the next escalation step or temporarily reduce the dose. Liquid calories — protein-rich smoothies, milk-based drinks — can fill gaps when solid food feels difficult. Always raise persistent under-eating with the prescribing clinician.

Do I need to keep tracking calories forever on a GLP-1?

Not necessarily, but the data is most useful when dose changes are being considered or when weight loss has stalled. Many users transition from daily logging to weekly check-ins once intake is stable and the prescribed dose is established. The calorie tracking versus intuitive eating discussion covers the longer-term decision. What clinicians value most is intake data at the moments dose decisions are made.

What side effects affect calorie intake most?

Delayed gastric emptying — recognised by the TGA in safety alerts for the GLP-1 and GIP/GLP-1 class — is the dominant driver. The same mechanism that produces satiety and weight loss produces nausea, early satiety, reflux, and occasionally vomiting, particularly during the first 2 weeks after each dose increase. Smaller more frequent meals, slower eating, and lower-fat preparations all help. Constipation is also common and usually manageable with fluid and fibre. Any persistent severe gastrointestinal symptoms — particularly abdominal pain — warrant a prompt call to the prescribing clinician.

Sources